Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 7.22%12.3B | 16.17%10.63B | 2.19%11.83B | 6.96%44.39B | 5.82%12.19B | 0.43%11.47B | 6.35%9.15B | 16.30%11.57B | 24.75%41.5B | 38.10%11.52B |
Cost of revenue | 0.95%5.06B | 12.17%4.5B | 1.97%5.04B | 11.90%19.34B | 3.14%5.37B | 10.47%5.01B | 17.12%4.01B | 20.24%4.95B | 36.80%17.29B | 66.18%5.21B |
Gross profit | 12.09%7.24B | 19.29%6.13B | 2.35%6.78B | 3.43%25.04B | 8.03%6.82B | -6.19%6.46B | -0.77%5.14B | 13.53%6.63B | 17.37%24.21B | 21.19%6.31B |
Operating expense | 1.61%5.82B | 10.68%6.23B | 13.38%5.99B | 2.27%22.83B | 3.00%6.19B | -0.43%5.73B | 4.77%5.63B | 1.85%5.29B | 16.13%22.33B | 13.68%6.01B |
Selling and administrative expenses | 1.81%5.83B | 10.68%6.23B | 13.38%5.99B | 2.27%22.83B | 3.00%6.19B | -0.43%5.73B | 4.77%5.63B | 1.85%5.29B | 16.13%22.33B | 13.68%6.01B |
-General and administrative expense | 1.81%5.83B | 10.68%6.23B | 13.38%5.99B | 2.27%22.83B | 3.00%6.19B | -0.43%5.73B | 4.77%5.63B | 1.85%5.29B | 16.13%22.33B | 13.68%6.01B |
Operating profit | 94.23%1.42B | 79.61%-99.85M | -41.12%789.85M | 17.13%2.21B | 109.01%626.1M | -35.48%730.28M | -152.65%-489.71M | 107.16%1.34B | 34.36%1.89B | 473.75%299.56M |
Net non-operating interest income (expenses) | 3.52%-55.66M | -6.95%-59.72M | 14.55%-48.09M | 16.88%-221.89M | 23.38%-52.07M | 10.55%-57.69M | 16.13%-55.84M | 17.12%-56.28M | -4.04%-266.94M | -2.68%-67.96M |
Non-operating interest income | 10.60%668K | 94.01%1.1M | -15.62%713K | 89.35%2.79M | 158.00%774K | -29.93%604K | 238.10%568K | 486.81%845K | 230.49%1.47M | 79.64%300K |
Non-operating interest expense | -3.37%56.33M | 7.83%60.82M | -14.57%48.81M | -16.30%224.68M | -22.58%52.85M | -10.81%58.3M | -15.49%56.4M | -16.05%57.13M | 4.43%268.42M | 2.87%68.26M |
Net investment income | -3,372.85%-593.16M | 14.30%230.32M | 1,007.65%285.49M | -105.66%-76.65M | 59.08%-229.62M | -104.50%-17.08M | -77.54%201.5M | -104.93%-31.45M | 1,593.10%1.35B | -14,735.37%-561.12M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 0 | 59K | -1,655.19%-12.43M | -100.69%-59.89M | -64.78M | -49.72%4.08M | 0 | -99.99%799K | 32,899.14%8.64B | 0 |
Less:Other special charges | --0 | ---59K | 1,655.19%12.43M | 99.94%-5.53M | ---650K | 49.72%-4.08M | --0 | 99.99%-799K | -32,899.14%-8.64B | --0 |
Less:Write off | ---- | ---- | ---- | --65.43M | ---- | ---- | ---- | ---- | --0 | ---- |
Other non-operating income (expenses) | -243.52%-4.95M | 1,100.23%17.26M | -118.45%-2.53M | 16.26%12.38M | -418.04%-3.09M | 60.57%3.45M | -284.40%-1.73M | 108.45%13.74M | 112.28%10.64M | 713.92%970K |
Income before tax | 15.33%764.68M | 125.47%88.07M | -20.18%1.01B | -83.98%1.86B | 184.17%276.54M | -54.49%663.04M | -154.35%-345.77M | -87.14%1.27B | 1,068.04%11.63B | -130.31%-328.55M |
Income tax | 25.19%348.31M | 135.34%205.71M | 66.50%513.84M | -74.43%772.03M | 112.85%97.79M | -43.59%278.21M | -62.96%87.41M | -89.89%308.62M | 905.03%3.02B | 0.85%-760.82M |
Net income | 8.20%416.37M | 72.84%-117.63M | -48.06%498.44M | -87.33%1.09B | -58.65%178.76M | -60.07%384.82M | -208.23%-433.18M | -85.91%959.58M | 527.98%8.61B | -30.80%432.26M |
Net income continuous operations | 8.20%416.37M | 72.84%-117.63M | -48.06%498.44M | -87.33%1.09B | -58.65%178.76M | -60.07%384.82M | -208.23%-433.18M | -85.91%959.58M | 527.98%8.61B | -30.80%432.26M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 8.20%416.37M | 72.84%-117.63M | -48.06%498.44M | -87.33%1.09B | -58.65%178.76M | -60.07%384.82M | -208.23%-433.18M | -85.91%959.58M | 527.98%8.61B | -30.80%432.26M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 8.20%416.37M | 72.84%-117.63M | -48.06%498.44M | -87.33%1.09B | -58.65%178.76M | -60.07%384.82M | -208.23%-433.18M | -85.91%959.58M | 527.98%8.61B | -30.80%432.26M |
Gross dividend payment | ||||||||||
Basic earnings per share | 38.00%4.83 | 72.84%-1.07 | -48.05%4.54 | -87.34%9.93 | -58.63%1.63 | -60.14%3.5 | -208.24%-3.94 | -85.92%8.74 | 527.86%78.42 | -30.76%3.94 |
Diluted earnings per share | 9.08%3.8179 | 72.84%-1.072 | -48.05%4.54 | -87.34%9.93 | -58.65%1.629 | -60.14%3.5 | -208.45%-3.9476 | -85.92%8.74 | 527.86%78.42 | -30.77%3.9393 |
Dividend per share | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |